Full-Time

Global HCM Therapeutic Lead

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$1 - $350kHourly

Senior

Remote in USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • MD/DO (cardiovascular and HCM training and clinical research and/or Medical Affairs experience preferred, board certification/eligibility desirable) with 8+ years of related experience
  • Medical Affairs experience with medicine approvals and peri-launch activities
  • Background in academic medicine, clinical research, and familiarity with biostatistics and epidemiology are highly desirable
  • Prior experience in the biotech/pharmaceutical industry is a plus
  • Familiarity with OPDP, PhRMA code, and key regulations in the pharmaceutical industry is a plus
  • Proven ability to work independently and as a member of an integrated, interdisciplinary team in carrying out assigned responsibilities
  • Must be analytical and articulate in both oral and writing skills, possess excellent presentation skills, with a demonstrated ability to communicate well with others at varying professional levels
  • Proficiency with Microsoft Office
  • Ability to travel domestically and internationally (~30% of the time)
Responsibilities
  • Serve as the Global Medical Affairs lead for the launch of aficamten, including development of strategic vision, execution of medical launch activities, and education of HCPs
  • Lead and manage day‐to‐day clinical and medical guidance while working closely on joint projects with other members of the Medical Affairs team and other departments within Cytokinetics and our business partners. Projects may include scientific congress/conference strategy and planning, advisory boards, field force training, review of medical information standard response letters, health economics and epidemiology analyses, and marketing/policy related projects.
  • Partner with European and ex-US Medical Affairs and cross-functional personnel to assure global harmonization of aficamten efforts and data promulgation
  • Expand and maintain an active global KOL HCM expert network
  • Lead scientific input into publication strategy for the HCM therapeutic area, including review of abstracts and posters for presentation at scientific meetings and manuscripts for publication
  • Establish the scientific and clinical priorities for an investigator sponsored study program and chair the internal review committee that adjudicates submitted research proposals
  • Serve as Medical lead on appropriate cross‐functional Medical and Commercial teams to inform brand strategies and tactics for aficamten
  • Lead strategic planning and implementation of HCM medical education, grant, and sponsorship programs
  • Provide clinical and scientific support in responding to inquiries from healthcare professionals
  • Support the Medical Affairs review of medical and promotional scientific materials related to HCM and aficamten
  • Present data at company advisory board meetings and training programs
  • Lead specific data generation projects to address identified medical data gaps
  • Identify and effectively interact with HCM external experts to engage in scientific exchange to meet the needs of patients and the medical community
  • Collaborate with HEOR function to define HCM research strategy and design of studies
  • Lead Medical content for Medical Affairs initiatives including collaboration with the MSL team including the development of materials for external medical interactions and to address healthcare professional inquiries
  • Upon initiation of a Phase 4 program, lead the review and adjudication of investigator-initiated research proposals

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, depending on the condition being treated. For example, they are working on drugs for heart failure, hypertrophic cardiomyopathy, amyotrophic lateral sclerosis, and spinal muscular atrophy. What sets Cytokinetics apart from competitors is their specific focus on muscle-related conditions and their extensive pipeline of drugs currently in clinical trials. The company's goal is to bring effective treatments to market that address the unmet needs of patients suffering from these debilitating diseases.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Phase III trial results for aficamten in treating obstructive hypertrophic cardiomyopathy (HCM) highlight the company's potential for market leadership in this area.
  • The $575M funding from Royalty Pharma ensures strong financial support for the commercial launch of aficamten and further R&D activities.
  • Recent investments and stock offerings indicate strong investor confidence and provide additional capital for growth and development.

What critics are saying

  • The late-stage biopharmaceutical market is highly competitive, with significant pressure to bring drugs to market quickly and efficiently.
  • Dependence on the success of clinical trials and regulatory approvals poses inherent risks, as any setbacks could delay commercialization and revenue generation.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle function improvement for cardiovascular and neuromuscular diseases, a niche area with high unmet medical needs.
  • The company has a robust pipeline of small molecule muscle activators and inhibitors, setting it apart from competitors with more generalized drug portfolios.
  • Strategic funding collaborations, such as the $575M deal with Royalty Pharma, provide significant financial backing for their R&D and commercialization efforts.

Help us improve and share your feedback! Did you find this helpful?